Abdominal Binders to Treat Orthostatic Hypotension in Parkinsonian Syndromes — ABOH-PS  

Parkinson Disease Clinical Trial

Official title: Abdominal Binders to Treat Orthostatic Hypotension in Parkinsonian Syndromes: a Randomized, Placebo-controlled, Double-blind, Crossover Phase II Trial

Status Recruiting

Clinical Trial Summary

The purpose of the present clinical trial is to determine whether the use of an elastic abdominal binder is effective in the non-pharmacological management of symptomatic, neurogenic orthostatic hypotension (OH) in individuals suffering from Parkinson's disease (PD) or Parkinson variant multiple system atrophy (MSA-P).

Clinical Trial Description

This is a monocentric, randomized, placebo-controlled, double-blind, crossover phase II clinical trial with an open-label treatment extension phase. The investigators plan to recruit n = 30 individuals with MSA-P or PD with known or suspected OH. At the Screening Visit, after patient information and written informed consent, the participants will first undergo a comprehensive neurological and cardiological evaluation, as well cardiovascular autonomic function testing to confirm the diagnosis of symptomatic, neurogenic OH. Afterwards, the participants will be asked to wear physical activity monitoring (PAM) sensors for five consecutive days and to measure the blood pressure (BP) regularly following a home BP diary (i.e. Home Phase I). On treatment day-1 (i.e. Visit 1), the participants will undergo an instrumented in-lab gait analysis, followed by a head-up tilt and active standing test. Afterwards, they will wear the first type of binder for two hours (either the investigational elastic abdominal binder or the placebo-comparator binder, depending on the randomization assignment). At the end of the two hours, the participants will repeat the in-lab gait analysis and the head-up tilt-/active standing test. After one-day wash-out, the same procedure of treatment day-1 (i.e. Visit 1) will be repeated with the outstanding type of binder (i.e. treatment day-2, Visit 2). At the end of this, all participants will be invited to wear the investigational elastic abdominal binder and the PAM sensors for five more days and to repeat the home BP measurements (i.e. Home Phase II). A final follow-up visit is scheduled to return the PAM sensors, the BP monitor and to detect eventual adverse and serious adverse events occurred during Home Phase II. ;

Related Conditions & MeSH terms

• Hypotension
• Hypotension, Orthostatic
• Multiple System Atrophy
• Orthostatic; Hypotension, Neurogenic
• Parkinson Disease
• Parkinsonian Disorders
• Shy-Drager Syndrome

• NCT number: NCT04920552
• Study type: Interventional
• Source: Universitätsklinik für Neurologie, Innsbruck
• Contact: Gregor K. Wenning, Prof. DDr. MSc
• Phone: 004351250481811
• Email: gregor.wenning@i-med.ac.at
• Status: Recruiting
• Phase: N/A
• Start date: May 17, 2021
• Completion date: June 2025